TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from ANGLE plc ( (GB:CLBX) ) is now available.
CelLBxHealth plc announced an update regarding the admission of fundraising shares following an oversubscribed placing. The first tranche of 9,090,000 shares is expected to be admitted on December 16, 2025, with a second tranche of up to 770,910,000 shares expected by December 18, 2025. This development is significant for the company’s operations as it reflects strong investor interest and could enhance its market positioning by increasing capital for further advancements in its CTC solutions.
The most recent analyst rating on (GB:CLBX) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on GB:CLBX Stock
According to Spark, TipRanks’ AI Analyst, GB:CLBX is a Neutral.
ANGLE plc’s overall stock score is primarily impacted by its poor financial performance and valuation, indicating significant challenges. Technical analysis also suggests bearish momentum. While the earnings call highlighted some positive developments, the need for additional funding and adverse market conditions weigh heavily on the stock’s outlook.
To see Spark’s full report on GB:CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a CTC intelligence company specializing in innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. Its patent-protected Parsortix® platform is designed to harvest CTCs from blood, integrating with laboratory instruments for comprehensive analysis, including imaging, proteomic profiling, and genomic workflows. The company focuses on product sales, lab-developed tests, and laboratory services, with a GCLP certified UK laboratory supporting clinical trials and assay development.
Average Trading Volume: 2,808,861
Technical Sentiment Signal: Sell
Current Market Cap: £5.16M
See more data about CLBX stock on TipRanks’ Stock Analysis page.